Malaria (Plasmodium Falciparum)
8
2
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Malaria CVD 36000; Gates INV090205
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
Dose Finding Trial of R21/Matrix-M in School Children
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
Clinical Study of Meplazumab to Treat With Malaria